A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)

The main inclusion criteria include but are not limited to: * Adult participants must be age 18 or older * Pediatric participants must be at least 2 years old and less than 18 years old. * Diagnosis of precursor B-cell acute lymphoblastic leukemia (B-ALL) and have more than 5% blasts in the bone marrow by morphological assessment * Participants with Ph-negative B-ALL with any of the following refractory/relapse criteria: * Failure to achieve complete remission after initial induction therapy; * Failure to achieve complete remission after salvage treatment; * Relapse with first remission duration ≤12 months * Second or later relapse * Relapse after allogeneic HSCT * Participants with Ph-positive B-ALL who have received 2 (or more) tyrosine kinase inhibitors (TKIs) and meet the refractory/relapse criteria above or, those with the T315I mutation The main exclusion criteria include but are not limited to: * History of Burkitt's leukemia. * Received anti-CD19 therapy within 3 months prior to entering the study * Received allogeneic HSCT within 12 weeks prior to entering the study * Received prior treatment with chimeric antigen receptor T cell (CAR-T) within 3 months prior to entering the study * History or presence of clinically relevant central nervous system (CNS) pathology * History of clinically symptomatic metastases to the central nervous system or meninges, or other evidence of uncontrolled metastases to the CNS or meninges * History of immunodeficiency, including history of any positive test result for human immunodeficiency virus (HIV) antibody. * History of serious cardiovascular and cerebrovascular disease * Has active autoimmune diseases that may relapse